Institutional Infrastructure
for Venture Capital
Syndication & Co-Investment

New York-based fintech startup Zenskar has raised $15 million in a Series A funding round to expand its AI-powered revenue automation platform, as enterprises increasingly seek intelligent systems to manage complex billing and finance operations.The round was led by Susquehanna Venture Capital, Bessemer Venture Partners, Shine Capital, and Rho, with participation from Rocketship, J-Ventures, Future Back Ventures by Bain & Company, and Converge. The investment reflects growing confidence in AI-native infrastructure for modern finance teams.Founded to solve the growing complexity of B2B monetization models, Zenskar provides an automation platform for usage-based billing, subscriptions, invoicing, collections, revenue recognition, and financial operations. Its platform is designed for companies managing dynamic pricing models that traditional ERP and billing tools struggle to support.The company describes its vision as “Zero-Touch Finance,” where AI agents handle repetitive finance workflows with minimal manual intervention. These agentic capabilities are expected to automate tasks such as billing operations, reconciliation, contract interpretation, collections workflows, and revenue reporting.As SaaS, AI, cloud, and infrastructure companies increasingly adopt hybrid pricing models combining subscriptions, usage, seats, and outcome-based pricing, finance teams face rising operational complexity. Zenskar is positioning itself as a next-generation solution built specifically for this shift in B2B revenue models.The newly raised capital will be used to deepen Zenskar’s AI product stack, accelerate enterprise go-to-market expansion, and strengthen integrations across ERP, CRM, and payments ecosystems.As finance operations evolve from back-office processes into strategic growth functions, Zenskar is emerging as a key player at the intersection of fintech, enterprise AI, and revenue intelligence.

AI-powered customer experience startup Solidroad has raised $25 million in a Series A funding round, as enterprises increasingly seek smarter ways to maintain service quality across both human and AI-led customer support channels.The round was led by Hedosophia, with participation from First Round Capital, Y Combinator, and Sony Innovation Fund, reflecting growing investor confidence in next-generation customer support infrastructure. The funding brings Solidroad’s total capital raised to more than $30 million.Founded in 2023, Solidroad has built an AI-native platform that automatically evaluates 100% of customer interactions across chat, email, and voice channels. Unlike traditional quality assurance systems that manually review only a small sample of conversations, Solidroad analyzes every interaction to identify risks, training gaps, and opportunities to improve customer satisfaction.The platform also converts performance insights into personalized coaching simulations and training workflows, helping support teams improve service standards without increasing headcount. This has become especially valuable as companies deploy AI agents at scale while still needing consistent quality oversight.Solidroad already serves a growing customer base that includes Ryanair, ŌURA, Crypto.com, ActiveCampaign, Tech Mahindra, and PartnerHero. The company says its system has scored millions of interactions and improved analyst productivity by up to 10x.The newly raised capital will be used to expand teams across San Francisco and Dublin, deepen enterprise integrations, and accelerate product development as demand rises for AI-enabled customer operations tools.As businesses increasingly blend human agents with AI systems, Solidroad is positioning itself as a critical quality layer for the future of customer support where speed, consistency, and customer satisfaction must scale together.

UK-based biotech startup Storm Therapeutics has closed a $56 million Series C funding round to accelerate the clinical development of its lead oncology program, reinforcing investor confidence in next-generation RNA-targeting cancer therapies.The newly raised capital will primarily be used to advance STC-15 through Phase II clinical trials across multiple indications, with the company aiming to generate data that could support accelerated regulatory approval pathways.Storm Therapeutics is focused on targeting RNA-modifying enzymes involved in disease progression. Its lead candidate, STC-15, inhibits METTL3, an enzyme responsible for messenger RNA methylation—a process increasingly recognized as a key driver in tumor growth and cancer cell survival.The upcoming Phase II studies will evaluate STC-15 in selected sarcoma indications. Sarcomas are rare but aggressive cancers affecting bone, muscle, fat, cartilage, blood vessels, and connective tissues. These tumors often respond poorly to conventional targeted therapies or immunotherapies, creating significant unmet medical need.According to available early-stage clinical data, STC-15 demonstrated durable tumor regression across multiple sarcoma subtypes in Phase I testing, increasing optimism around its differentiated mechanism of action. By disrupting METTL3-driven biology, the therapy aims to induce cell-cycle arrest and apoptosis in malignant cells.Storm Therapeutics has emerged as one of Europe’s more closely watched precision oncology biotech companies, positioning itself within the rapidly expanding field of epitranscriptomics an area exploring how RNA modifications can be harnessed for therapeutic innovation.With fresh capital secured, the company is now focused on translating promising science into late-stage clinical progress, potentially opening a new treatment avenue for patients with difficult-to-treat cancers.

US-based healthtech startup Ethermed has raised $8.5 million in a Series A funding round, bringing its total funding to over $15 million as demand rises for AI-driven solutions that reduce administrative burdens across healthcare systems.The round was led by Enfield Capital Partners and Blue Marlin Partners, with participation from Jumpstart Ventures, Healthliant Ventures, Woodard Family Office, and Gaingels, reflecting strong investor confidence in the modernization of healthcare operations.Founded to solve one of healthcare’s most persistent inefficiencies, Ethermed has built an intelligent automation platform focused on prior authorization and medical-necessity workflows. Its technology uses advanced language models and clinical reasoning to interpret payer rules, review documentation, and generate compliant submissions in seconds.Prior authorization remains a major bottleneck for providers, often delaying treatments for days while staff manually compile paperwork and navigate insurer requirements. Ethermed’s platform aims to compress these timelines from days to minutes, allowing care teams to spend more time on patients rather than paperwork.The company has already integrated with leading electronic health record systems and processed millions of prior authorization transactions, demonstrating measurable reductions in denials, turnaround times, and staff workload. Ethermed currently serves a growing base of provider and payer customers across the United States.The newly raised capital will be used to accelerate enterprise deployments, deepen partnerships with health systems, expand engineering and data science teams, and further enhance its AI engine for clinical workflows.As healthcare organizations increasingly seek automation to control costs and improve patient access, Ethermed is positioning itself as a next-generation infrastructure provider at the intersection of AI, clinical operations, and healthcare administration.

Software startups are fast becoming less about product competition and more about- Distribution- Speed- Access to capitalBecause:- Good software building is now weeks and months, not years.- AI has compressed the cost of building.- But it has not reduced the cost of winning.So what actually matters now?1. Can you get in front of users faster than others?2. Can you iterate before others even launch?3. Can you survive long enough to matter?In this environment, execution is the only moat left.VCs and VC-backed founders join www.newnex.io#startups #products #startups #venturecapital

AI cloud infrastructure startup Parasail has raised $32 million in a Series A funding round, as demand surges for scalable and cost-efficient compute solutions powering the next wave of AI applications and autonomous agents.The round was co-led by Touring Capital and Kindred Ventures, with participation from Samsung NEXT, Flume Ventures, Banyan Ventures, and existing investors, reflecting strong confidence in the rapidly evolving AI infrastructure market.Founded to simplify how developers deploy and scale AI models, Parasail is building what it calls an “AI Supercloud” a global compute layer that aggregates GPU resources from multiple providers and optimizes them for performance, cost, and scalability.As AI adoption accelerates, companies are increasingly moving away from centralized cloud providers toward more flexible, distributed compute systems. Parasail addresses this shift by enabling developers to deploy production-ready AI endpoints within minutes, without the need for complex infrastructure management or long-term contracts.The platform is designed to power AI agents and modern applications that require high-volume inference workloads, processing over 500 billion tokens daily across a global network of data centers.With the newly raised capital, Parasail plans to expand its AI Supercloud capabilities, enhance inference optimization, and strengthen partnerships across the global GPU and data center ecosystem.As the AI ecosystem shifts toward agent-based architectures and open models, infrastructure providers like Parasail are emerging as critical enablers, bridging the gap between fragmented compute supply and the growing demand for scalable, developer-controlled AI systems.